Enliven Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2019 to Q2 2024

Taxonomy & unit: us-gaap: USD
Description: Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary: Enliven Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2019 to Q2 2024.
Enliven Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $5.14M, a 22.6% increase year-over-year.
Enliven Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $16.1M, a 94.3% increase year-over-year.
Enliven Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $12.9M, a 305% increase from 2022.
Enliven Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $3.19M, a 65.9% increase from 2021.
Enliven Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $1.92M, a 13.8% decline from 2020.

Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)

Share-based Payment Arrangement, Expense, Quarterly (USD)

Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
Q2 2024	$16.1M	$5.14M	+$949K	+22.6%	Apr 1, 2024	Jun 30, 2024	10-Q	2024-08-13
Q1 2024	$15.2M	$4.52M	+$2.25M	+99.6%	Jan 1, 2024	Mar 31, 2024	10-Q	2024-05-14
Q4 2023	$12.9M	$3.06M	+$2.32M	+316%	Oct 1, 2023	Dec 31, 2023	10-K	2024-03-14
Q3 2023	$10.6M	$3.4M	+$2.3M	+209%	Jul 1, 2023	Sep 30, 2023	10-Q	2023-11-09
Q2 2023	$8.29M	$4.2M	+$3.49M	+498%	Apr 1, 2023	Jun 30, 2023	10-Q	2024-08-13
Q1 2023	$4.8M	$2.26M	+$1.61M	+246%	Jan 1, 2023	Mar 31, 2023	10-Q	2024-05-14
Q4 2022	$3.19M	$735K	+$1.68M		Oct 1, 2022	Dec 31, 2022	10-K	2024-03-14
Q3 2022	$1.51M	$1.1M	+$98K	+9.77%	Jul 1, 2022	Sep 30, 2022	10-Q	2023-11-09
Q2 2022	$1.42M	$701K	-$216K	-23.6%	Apr 1, 2022	Jun 30, 2022	10-Q	2023-08-10
Q1 2022	$1.63M	$654K	-$293K	-30.9%	Jan 1, 2022	Mar 31, 2022	10-Q	2023-05-11
Q4 2021	$1.92M	-$943K	-$1.62M	-239%	Oct 1, 2021	Dec 31, 2021	8-K	2023-06-23
Q3 2021	$3.55M	$1M	+$361K	+56.2%	Jul 1, 2021	Sep 30, 2021	10-Q	2022-10-25
Q2 2021	$3.19M	$917K	+$367K	+66.7%	Apr 1, 2021	Jun 30, 2021	10-Q	2022-08-03
Q1 2021	$2.82M	$947K	+$587K	+163%	Jan 1, 2021	Mar 31, 2021	10-Q	2022-05-06
Q4 2020	$2.23M	$679K	+$382K	+129%	Oct 1, 2020	Dec 31, 2020	10-K	2022-03-15
Q3 2020	$1.85M	$642K	+$332K	+107%	Jul 1, 2020	Sep 30, 2020	10-Q	2021-11-09
Q2 2020	$1.52M	$550K	+$353K	+179%	Apr 1, 2020	Jun 30, 2020	10-Q	2021-08-06
Q1 2020	$1.16M	$360K	+$265K	+279%	Jan 1, 2020	Mar 31, 2020	10-Q	2021-05-11
Q4 2019	$899K	$297K			Oct 1, 2019	Dec 31, 2019	10-K	2021-03-05
Q3 2019		$310K			Jul 1, 2019	Sep 30, 2019	10-Q	2020-11-05
Q2 2019		$197K			Apr 1, 2019	Jun 30, 2019	10-Q	2020-08-14
Q1 2019		$95K			Jan 1, 2019	Mar 31, 2019	10-Q	2020-05-07

* An asterisk sign (*) next to the value indicates that the value is likely invalid.